Now, the picture is shifting, and the odds are good that one of these players will pull ahead of the other, thereby becoming the better biotech-stock investment. The only questions are, which will it be, and for how long will it last? Let's dive in. In the future, the company hopes to pick up an indication for more severe forms of fibrosis as well as cirrhosis, and it's currently pursuing clinical trials on that front. Being able to treat cirrhosis would expand its addressable market significantly, but inve ...